References
- Martin P, Awan AA, Berenguer MC, et al. Executive summary of the KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2022;102(6):1228–1237.
- Jonny J, Teressa M. Expanded hemodialysis: a new concept of renal replacement therapy. J Investig Med. 2023;71(1):38–41.
- Bello AK, Levin A, Lunney M, et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019;367:l5873.
- Wang Y, Gao L. Inflammation and cardiovascular disease associated with hemodialysis for End-Stage renal disease. Front Pharmacol. 2022;13:800950.
- Campo S, Lacquaniti A, Trombetta D, et al. Immune system dysfunction and inflammation in hemodialysis patients: two sides of the same coin. J Clin Med. 2022;11:3759.
- Moradi H, Streja E, Vaziri ND. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients? Semin Dial. 2018;31(4):398–405.
- Canaud B, Kooman JP, Selby NM, et al. Dialysis-Induced cardiovascular and multiorgan morbidity. Kidney Int Rep. 2020;5(11):1856–1869.
- Shimizu A, Sonoda S, Muraoka Y, et al. Bleeding and ischemic events during dual antiplatelet therapy after second-generation drug-eluting stent implantation in hemodialysis patients. J Cardiol. 2019;73(6):470–478.
- Lin TY, Chou HH, Hsieh TH, et al. Malnutrition is associated with increased morbidity and death in dialysis patients undergoing endovascular therapy for peripheral artery disease. Eur J Vasc Endovasc Surg. 2022;64(2–3):225–233.
- Khoo CY, Gao F, Choong HL, et al. Death and cardiovascular outcomes in end-stage renal failure patients on different modalities of dialysis. Ann Acad Med Singap. 2022;51(3):136–142.
- Pfau A, Ermer T, Coca SG, et al. High oxalate concentrations correlate with increased risk for sudden cardiac death in dialysis patients. J Am Soc Nephrol. 2021;32(9):2375–2385.
- Lee B. Neuroprotective effect of acupuncture against single prolonged Stress-Induced memory impairments and inflammation in rat brain via modulation of Brain-Derived neurotrophic factor expression. Evid Based Complement Alternat Med. 2022;2022:4430484.
- Bi C, Fu Y, Li B. Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway. Cell Signal. 2020;70:109569.
- Tsuchida A, Nonomura T, Nakagawa T, et al. Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Diabetes Obes Metab. 2002;4(4):262–269.
- Wu XJ, Shu QQ, Wang B, et al. Acetoacetate improves memory in alzheimer’s mice via promoting Brain-Derived neurotrophic factor and inhibiting inflammation. Am J Alzheimers Dis Other Demen. 2022;37:15333175221124949.
- Huo Y, Feng Q, Fan J, et al. Serum brain-derived neurotrophic factor in coronary heart disease: correlation with the T helper (Th)1/Th2 ratio, Th17/regulatory T (treg) ratio, and major adverse cardiovascular events. J Clin Lab Anal. 2023;37:e24803.
- Jung SM, Kim CT, Kang EW, et al. Dementia is a risk factor for major adverse cardiac and cerebrovascular events in elderly korean patients initiating hemodialysis: a korean national population-based study. BMC Nephrol. 2017;18(1):128.
- Eraldemir FC, Ozsoy D, Bek S, et al. The relationship between brain-derived neurotrophic factor levels, oxidative and nitrosative stress and depressive symptoms: a study on peritoneal dialysis. Ren Fail. 2015;37(4):722–726.
- Miyazaki S, Iino N, Koda R, et al. Brain-derived neurotrophic factor is associated with sarcopenia and frailty in japanese hemodialysis patients. Geriatr Gerontol Int. 2021;21(1):27–33.
- Shin SJ, Yoon HE, Chung S, et al. Plasma brain-derived neurotrophic factor in hemodialysis patients. Int J Med Sci. 2012;9(9):772–777.
- Shoji T. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clin Exp Nephrol. 2014;18(2):257–260.
- Zhao P, Li X, Li Y, et al. Mechanism of miR-365 in regulating BDNF-TrkB signal axis of HFD/STZ induced diabetic nephropathy fibrosis and renal function. Int Urol Nephrol. 2021;53(10):2177–2187.
- Alshogran OY, Khalil AA, Oweis AO, et al. Association of brain-derived neurotrophic factor and interleukin-6 serum levels with depressive and anxiety symptoms in hemodialysis patients. Gen Hosp Psychiatry. 2018;53:25–31.
- Keeler JL, Patsalos O, Chung R, et al. Short communication: serum levels of brain-derived neurotrophic factor and association with pro-inflammatory cytokines in acute and recovered anorexia nervosa. J Psychiatr Res. 2022;150:34–39.
- Gao J, Liang Z, Zhao F, et al. Triptolide inhibits oxidative stress and inflammation via the microRNA-155–5p/brain-derived neurotrophic factor to reduce podocyte injury in mice with diabetic nephropathy. Bioengineered. 2022;13(5):12275–12288.
- Alomari MA, Khalil H, Khabour OF, et al. Lipid profile in parkinson’s disease: the potential role of brain-derived neurotrophic factor. Life Sci. 2022;311(Pt A):121144.
- Taşçı İ, Kabul HK, Aydoğdu A. Brain derived neurotrophic factor (BDNF) in cardiometabolic physiology and diseases. Anadolu Kardiyol Derg. 2012;12(8):684–688.
- Mojtabavi H, Shaka Z, Momtazmanesh S, et al. Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis. J Transl Med. 2022;20(1):126.
- Zierold S, Buschmann K, Gachkar S, et al. Brain-Derived neurotrophic factor expression and signaling in different perivascular adipose tissue depots of patients with coronary artery disease. J Am Heart Assoc. 2021;10:e018322.
- Wang BL, Jin H, Han XQ, et al. Involvement of brain-derived neurotrophic factor in exercise‑induced cardioprotection of post-myocardial infarction rats. Int J Mol Med. 2018;42(5):2867–2880.